Cardiology Today -- Rosuvastatin is now indicated for the primary prevention of CVD in adults with no clinically evident coronary heart disease. The FDA has approved rosuvastatin for the prevention of stroke, MI and arterial revascularization in a select population of adults, according to a press release.
